We are live on ! Find out more
AUTL

Autolus Therapeutics
AUTL

121 hedge funds and large institutions have $1.12B invested in Autolus Therapeutics in 2024 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 46 increasing their positions, 27 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

367% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 6

91% more call options, than puts

Call options by funds: $1.19M | Put options by funds: $625K

70% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 27

67% more funds holding in top 10

Funds holding in top 10: 3 → 5 (+2)

50% more capital invested

Capital invested by funds: $747M → $1.12B (+$374M)

22% more funds holding

Funds holding: 99 → 121 (+22)

0.57% less ownership

Funds ownership: 66.67% → 66.1% (-0.57%)

Holders
121
Holders Change
+22
Holders Change %
+22.22%
% of All Funds
1.74%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.07%
New
28
Increased
46
Reduced
27
Closed
6
Calls
$1.19M
Puts
$625K
Net Calls
+$566K
Net Calls Change
-$937K

Top Buyers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
+$77M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$67.1M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$56.2M
4
DM
Deerfield Management
New York
+$22.7M
5
DTC
Deep Track Capital
Connecticut
+$21.2M

Top Sellers

Rank Fund Capital Flow
1
PBA
Paradigm Biocapital Advisors
New York
-$38.6M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$3.9M
3
TAM
TFG Asset Management
Cayman Islands
-$2.96M
4
LCM
Lynx1 Capital Management
Puerto Rico
-$2.92M
5
UOC
UBS O'Connor
Illinois
-$2.39M
Name Holding Trade Value Shares
Change 		Change in
Stake
GPP
26
Great Point Partners
Connecticut
$7.44M +$7.28M +1,166,667 New
Marshall Wace
27
Marshall Wace
United Kingdom
$6.63M +$3.39M +542,724 +109%
RSCM
28
Rock Springs Capital Management
Maryland
$6.59M +$6.44M +1,032,988 New
Walleye Capital
29
Walleye Capital
New York
$5.29M -$133K -21,390 -3%
AI
30
Alphabet Inc
California
$4.45M – – –
Morgan Stanley
31
Morgan Stanley
New York
$4.41M +$3.29M +527,735 +324%
Citadel Advisors
32
Citadel Advisors
Florida
$4.38M +$4.03M +646,715 +1,626%
DCM
33
Driehaus Capital Management
Illinois
$4.31M +$4.22M +676,025 New
D.E. Shaw & Co
34
D.E. Shaw & Co
New York
$4.13M +$2.65M +425,470 +192%
LCP
35
LGT Capital Partners
Switzerland
$3.51M – – –
Voloridge Investment Management
36
Voloridge Investment Management
Florida
$3.27M +$3.2M +512,847 New
IHAM
37
Integral Health Asset Management
New York
$3.19M +$3.12M +500,000 New
MIM
38
Monashee Investment Management
Massachusetts
$3.14M +$3.07M +492,000 New
SSA
39
Schonfeld Strategic Advisors
New York
$2.74M -$818K -131,100 -23%
Nomura Asset Management
40
Nomura Asset Management
Japan
$2.45M +$2.4M +384,796 New
Millennium Management
41
Millennium Management
New York
$2.43M +$1.99M +319,798 +527%
Wells Fargo
42
Wells Fargo
California
$2.4M -$191K -30,678 -8%
MCM
43
MAI Capital Management
Ohio
$2.26M +$15K +2,400 +0.7%
TD Asset Management
44
TD Asset Management
Ontario, Canada
$2.18M +$1.29M +207,106 +153%
Renaissance Technologies
45
Renaissance Technologies
New York
$2.07M +$1.02M +164,300 +103%
HCA
46
Harbor Capital Advisors
Illinois
$1.78M -$179K -28,682 -9%
Arrowstreet Capital
47
Arrowstreet Capital
Massachusetts
$1.75M +$1.58M +252,601 +1,184%
Bank of America
48
Bank of America
North Carolina
$1.67M +$1.37M +220,235 +533%
HS
49
HighVista Strategies
Massachusetts
$1.67M +$1.63M +261,324 New
Two Sigma Investments
50
Two Sigma Investments
New York
$1.46M -$177K -28,414 -11%
1
2
3 4 5

AUTL Hedge Fund Activity: Q1 2024 in Review

121 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q1 2024, worth a combined $1.12B — up 50% from $747M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new AUTL positions and 6 closed out — a net gain of 22 holders — while 46 added to existing stakes and 27 trimmed.

The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $77M. The largest seller was Paradigm Biocapital Advisors, cutting an estimated $38.6M.

  • 121 institutional investors held Autolus Therapeutics (AUTL) as of Q1 2024, up from 99 in Q4 2023.
  • Funds reported $1.12B of Autolus Therapeutics stock for Q1 2024, up 50% quarter-over-quarter.
  • 28 funds opened new Autolus Therapeutics positions in Q1 2024 and 6 closed out, a net change of +22 holders.
  • The largest Autolus Therapeutics buyer in Q1 2024 was Avoro Capital Advisors, an estimated $77M added.
  • The largest Autolus Therapeutics seller in Q1 2024 was Paradigm Biocapital Advisors, an estimated $38.6M sold.

Based on aggregated 13F filings for Q1 2024.